
Voglibase 0.2mg Tablet MD
Marketer
Wallace Pharmaceuticals Pvt Ltd
Salt Composition
Voglibose (0.2mg)
Overview Voglibase 0.2mg Tablet MD
DiaBeta 0.2mg tablets are indicated for managing type 2 diabetes. This medication aids in post-prandial blood glucose regulation, employed when dietary modifications and other comparable treatments prove insufficient. DiaBeta 0.2mg should be administered immediately prior to meals; dosage frequency is determined by your physician to optimize glycemic control. Discontinuing treatment abruptly is inadvisable without medical consultation, as this may elevate blood sugar, potentially causing serious complications such as renal impairment or visual disturbances. Successful management necessitates a holistic approach incorporating diet, exercise, and weight control, as directed by your doctor. Regular blood glucose monitoring is essential. Common side effects include bloating, abdominal discomfort, anorexia, constipation, and diarrhea. Report persistent or bothersome adverse effects to your physician. DiaBeta alone does not typically induce hypoglycemia. However, concurrent use with other antidiabetic agents (particularly insulin or sulfonylureas) may increase hypoglycemic risk, requiring treatment with plain glucose (not sucrose). Prior to commencing treatment, disclose any liver or kidney conditions. This medication is contraindicated in patients with bowel inflammation or ulceration (e.g., ulcerative colitis, Crohn's disease). Pregnant or lactating individuals should consult their doctor before use. Inform your physician of all concurrent medications to ensure treatment safety. Excessive alcohol consumption should be avoided due to the heightened hypoglycemia risk.
Uses of Voglibase 0.2mg Tablet MD
Managing type 2 diabetes
Major Benefits of Voglibase 0.2mg Tablet MD:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment schedule. Avoid handling the tablets with damp hands. Place the tablet in your mouth, but refrain from swallowing immediately. Voglibase 0.2mg Tablet MD should be taken on an empty stomach.
Common Side effects of Voglibase 0.2mg Tablet MD:
- Skin rash
- Flatulence
- Abdominal pain
- Diarrhea
How to use Voglibase 0.2mg Tablet MD:
Administer this medication precisely as directed by your physician, adhering to both dosage and treatment length. Avoid handling the tablets with damp hands. Place the tablet in your mouth; however, refrain from swallowing immediately. Voglibase 0.2mg Tablet MD should be consumed on an empty stomach.
How Voglibase 0.2mg Tablet MD works:
MD-formulated Voglibase 0.2mg tablets offer anti-diabetic action by suppressing the activity of intestinal enzymes that digest complex carbohydrates. This mechanism reduces postprandial spikes in blood glucose.
SAFETY ADVICE
AlcoholUNSAFE
Combining Voglibase 0.2mg Tablet MD and alcohol is unsafe.
PregnancySAFE IF PRESCRIBED
The use of Voglibase 0.2mg Tablet MD during pregnancy is typically deemed safe. Preclinical trials in animals revealed minimal or no harmful consequences for the fetus; nevertheless, clinical data from human trials are scarce.
Breast feedingSAFE IF PRESCRIBED
Maternal use of Voglibase 0.2mg tablets during lactation is likely safe. Available human data indicate minimal risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Voglibase 0.2mg Tablet MD.
KidneyCAUTION
Patients with severe renal impairment should use Voglibase 0.2mg Tablet MD cautiously. Dosage modification of Voglibase 0.2mg Tablet MD may be necessary. Physician consultation is advised.
LiverCAUTION
Exercise caution when administering Voglibase 0.2mg Tablet MD to individuals suffering from advanced hepatic impairment. Dosage modification of Voglibase 0.2mg Tablet MD might be necessary. Physician consultation is advised.
What if you forget to take Voglibase 0.2mg Tablet MD :
Omit any missed Voglibase 0.2mg Tablet MD dose and resume your usual regimen. Avoid taking a double dose.
Facts to Know About Voglibase 0.2mg Tablet MD
| Label | Value |
|---|---|
| Chemical Type | Valiolamine analog |
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
| Behavior Class | Alpha-glucosidase inhibitors |
